CAMLINFINE Camlin Fine Q3 FY25 results (Oct–Dec 2024) and concall
Camlin Fine Sciences reported a 2% increase in Q3 FY25 revenue to Rs. 433.49 crores, driven by improved gross margins (48% to 50%) and operational EBITDA (10% to 12%). The Vanillin segment saw price improvements and increased output, with the Dahej plant targeting 70% utilization by FY25 end and 75% by FY26. The Blends business maintained its 15-20% growth trajectory, fueled by new customer acquisitions. The company also reduced gross debt to Rs. 600 crores following a successful rights issue and NCD repayment, while actively working to minimize losses from discontinued European operations.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 417 | 431 |
| EBITDA | 52 | 56 |
| Net profit | -116 | -7 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
